Agenus Reports Will Receive $20M Milestone Payment From Bristol Myers Related To Dosing Of First Patient For TIGIT Bispecific Antibody
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today